The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort

Author

  • Jingmei Li
  • Wei Xiong Wen
  • Martin Eklund
  • Anders Kvist
  • Mikael Eriksson
  • Helene Nordahl Christensen
  • Astrid Torstensson
  • Svetlana Bajalica-Lagercrantz
  • Alison M. Dunning
  • Brennan Decker
  • Jamie Allen
  • Craig Luccarini
  • Karen Pooley
  • Jacques Simard
  • Leila Dorling
  • Douglas F. Easton
  • Soo Hwang Teo
  • Per Hall
  • Åke Borg
  • Henrik Grönberg
  • Kamila Czene
Show all

Summary, in English

Breast cancer patients with BRCA1/2-driven tumors may benefit from targeted therapy. It is not clear whether current BRCA screening guidelines are effective at identifying these patients. The purpose of our study was to evaluate the prevalence of inherited BRCA1/2 pathogenic variants in a large, clinically representative breast cancer cohort and to estimate the proportion of BRCA1/2 carriers not detected by selectively screening individuals with the highest probability of being carriers according to current clinical guidelines. The study included 5,122 unselected Swedish breast cancer patients diagnosed from 2001 to 2008. Target sequence enrichment (48.48 Fluidigm Access Arrays) and sequencing were performed (Illumina Hi-Seq 2,500 instrument, v4 chemistry). Differences in patient and tumor characteristics of BRCA1/2 carriers who were already identified as part of clinical BRCA1/2 testing routines and additional BRCA1/2 carriers found by sequencing the entire study population were compared using logistic regression models. Ninety-two of 5,099 patients with valid variant calls were identified as BRCA1/2 carriers by screening all study participants (1.8%). Only 416 study participants (8.2%) were screened as part of clinical practice, but this identified 35 out of 92 carriers (38.0%). Clinically identified carriers were younger, less likely postmenopausal and more likely to be associated with familiar ovarian cancer compared to the additional carriers identified by screening all patients. More BRCA2 (34/42, 81.0%) than BRCA1 carriers (23/50, 46%) were missed by clinical screening. In conclusion, BRCA1/2 mutation prevalence in unselected breast cancer patients was 1.8%. Six in ten BRCA carriers were not detected by selective clinical screening of individuals.

Department/s

  • Familial Breast Cancer
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2019-03-01

Language

English

Pages

1195-1204

Publication/Series

International Journal of Cancer

Volume

144

Issue

5

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Cancer and Oncology

Keywords

  • BRCA1
  • BRCA2
  • breast cancer
  • clinical testing
  • next-generation sequencing
  • prediction
  • screening criteria

Status

Published

Research group

  • Familial Breast Cancer

ISBN/ISSN/Other

  • ISSN: 0020-7136